Our data thus suggests that PD-L1 correlated with the prognosis in ccRCC and targeting the PD-1/PD-L1 pathway may be therapeutically efficacious and should thus be considered in the treatment of RCC patients. Here, CD274 is linked to nonpapillary renal cell carcinoma.